» Articles » PMID: 9174186

In Vitro Activities of Ciprofloxacin and Rifampin Alone and in Combination Against Growing and Nongrowing Strains of Methicillin-susceptible and Methicillin-resistant Staphylococcus Aureus

Overview
Specialty Pharmacology
Date 1997 Jun 1
PMID 9174186
Citations 10
Authors
Affiliations
Soon will be listed here.
Abstract

We characterized the effects of ciprofloxacin and rifampin alone and in combination on Staphylococcus aureus in vitro. The effects of drug combinations (e.g., indifferent, antagonistic, or additive interactions) on growth inhibition were compared by disk approximation studies and by determining the fractional inhibitory concentrations. Bactericidal effects in log-phase bacteria and in nongrowing isolates were characterized by time-kill methods. The effect of drug combinations was dependent upon whether or not cells were growing and whether killing or growth inhibition was the endpoint used to measure drug interaction. Despite bactericidal antagonism in time-kill experiments, our in vitro studies suggest several possible explanations for the observed benefits in patients treated with a combination of ciprofloxacin and rifampin for deep-seated staphylococcal infections. Notably, when growth inhibition rather than killing was used to characterize drug interaction, indifference rather than antagonism was observed. An additive bactericidal effect was observed in nongrowing bacteria suspended in phosphate-buffered saline. While rifampin antagonized the bactericidal effects of ciprofloxacin, ciprofloxacin did not antagonize the bactericidal effects of rifampin. Each antimicrobial prevented the emergence of subpopulations that were resistant to the other.

Citing Articles

Drug combinations targeting antibiotic resistance.

Bognar B, Spohn R, Lazar V NPJ Antimicrob Resist. 2025; 2(1):29.

PMID: 39843924 PMC: 11721080. DOI: 10.1038/s44259-024-00047-2.


A study on antimicrobial activity of lysine-like peptoids for the development of new antimicrobials.

Kasturiarachchi J Arch Microbiol. 2025; 207(1):21.

PMID: 39745532 DOI: 10.1007/s00203-024-04227-6.


Comparing the Synergistic and Antagonistic Interactions of Ciprofloxacin and Levofloxacin Combined with Rifampin against Drug-Resistant : A Time-Kill Assay.

Kang Y, Chung D, Ko J, Huh K, Cho S, Kang C Antibiotics (Basel). 2023; 12(4).

PMID: 37107077 PMC: 10135007. DOI: 10.3390/antibiotics12040711.


Antibiotic combinations reduce Staphylococcus aureus clearance.

Lazar V, Snitser O, Barkan D, Kishony R Nature. 2022; 610(7932):540-546.

PMID: 36198788 PMC: 9533972. DOI: 10.1038/s41586-022-05260-5.


Use of affinity allows anti-inflammatory and anti-microbial dual release that matches suture wound resolution.

Haley R, Qian V, Learn G, von Recum H J Biomed Mater Res A. 2019; 107(7):1434-1442.

PMID: 30771234 PMC: 6527479. DOI: 10.1002/jbm.a.36658.


References
1.
Miller M, Wexler M, STEIGBIGEL N . Single and combination antibiotic therapy of Staphylococcus aureus experimental endocarditis: emergence of gentamicin-resistant mutants. Antimicrob Agents Chemother. 1978; 14(3):336-43. PMC: 352461. DOI: 10.1128/AAC.14.3.336. View

2.
Pascual A, Garcia I, Ramirez de Arellano E, Perea E . Activity of sparfloxacin on Staphylococcus epidermidis attached to plastic catheters. J Antimicrob Chemother. 1995; 36(2):425-30. DOI: 10.1093/jac/36.2.425. View

3.
Eng R, Smith S, Tillem M, Cherubin C . Rifampin resistance. Development during the therapy of methicillin-resistant Staphylococcus aureus infection. Arch Intern Med. 1985; 145(1):146-8. DOI: 10.1001/archinte.145.1.146. View

4.
Karchmer A . Staphylococcal endocarditis. Laboratory and clinical basis for antibiotic therapy. Am J Med. 1985; 78(6B):116-27. DOI: 10.1016/0002-9343(85)90374-2. View

5.
Chambers H, Hartman B, Tomasz A . Increased amounts of a novel penicillin-binding protein in a strain of methicillin-resistant Staphylococcus aureus exposed to nafcillin. J Clin Invest. 1985; 76(1):325-31. PMC: 423778. DOI: 10.1172/JCI111965. View